Skip to Content
Merck
All Photos(1)

Key Documents

SML1608

Sigma-Aldrich

Besifloxacin hydrochloride

≥98% (HPLC)

Synonym(s):

7-[-3-Aminoazepam-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H21ClFN3O3 · HCl
CAS Number:
Molecular Weight:
430.30
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to light brown

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

[H]Cl.OC(C1=CN(C2CC2)C3=C(Cl)C(N4CCCCC(N)C4)=C(F)C=C3C1=O)=O

Biochem/physiol Actions

Besifloxacin is a broad spectrum fourth-generation fluoroquinolone antibiotic.
Besifloxacin is a broad spectrum fourth-generation fluoroquinolone antibiotic. Besifloxacin is effective against gram positive and negative, aerobic and anerobic bacteria. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex generating persistent, covalent enzyme–DNA adducts, inhibiting DNA synthesis. Besifloxacin inhibits both DNA gyrase and topoisomerase IV at nearly equal concentrations. It is used clinically primarily in the treatment of bacterial conjunctivitis.
Besifloxacin stops the production of pro-inflammatory cytokines in vitro.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jean Deschênes et al.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 50(3), 184-191 (2015-06-05)
Acute bacterial conjunctivitis is a common infection of the ocular surface. Increasing rates of bacterial resistance have prompted the development of new antibiotics with improved activity against the bacterial species most often found in this disease. Besifloxacin is the first
Synthetic approaches to the 2009 new drugs
Liu K K C, et al.
Bioorganic & Medicinal Chemistry, 19(3), 1136-1154 (2011)
Alexander T Nguyen et al.
Cornea, 34(8), 967-971 (2015-06-16)
To present the clinical outcome of 3 cases of ocular surface infections by Mycobacterium chelonae treated with besifloxacin (0.6%, Besivance; Bausch & Lomb, Tampa, FL). In this retrospective review of a small case series, we reviewed the medical records of
Timothy L Comstock et al.
Clinical ophthalmology (Auckland, N.Z.), 4, 215-225 (2010-05-14)
Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service